PART I . Overview We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF cell-free protein synthesis platform. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that ...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001649094-26-000007 | EDGAR | 111K words |
| 2025-02-25 | 2024-12-31 | 0001649094-25-000028 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021145 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0000950170-23-004654 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002281 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001564590-21-016110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001649094-25-000114 | EDGAR | 65K words |
| 2025-08-06 | 2025-06-30 | 0001649094-25-000098 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001649094-25-000074 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001649094-24-000097 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001649094-24-000052 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021677 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059395 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039817 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018835 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022597 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015501 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008485 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001193125-26-067546 | EDGAR | 23K words |
| 2026-02-24 | 0001649094-26-000005 | EDGAR | — |
| 2026-02-02 | 0001193125-26-033578 | EDGAR | — |
| 2025-12-19 | 0001649094-25-000116 | EDGAR | — |
| 2025-11-04 | 0001649094-25-000112 | EDGAR | — |
| 2025-09-30 | 0001649094-25-000102 | EDGAR | — |
| 2025-08-06 | 0001649094-25-000096 | EDGAR | — |
| 2025-06-17 | 0001649094-25-000084 | EDGAR | — |
| 2025-05-07 | 0001649094-25-000073 | EDGAR | — |
| 2025-05-01 | 0001649094-25-000057 | EDGAR | — |
104 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649094 |
| Ticker | PCVX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.vaxcyte.com |
| Listed | 2020-06-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report